Our Mission

To prevent vision loss from glaucoma by investing in innovative research, education, and support with the ultimate goal of finding a cure.
Dear Friends,

Thanks to you and others who share the belief in our mission, 2013 was an exceptional year for Glaucoma Research Foundation. We celebrated our 35th anniversary, earned Charity Navigator’s “Exceptional” 4-star rating, and received the largest bequest in our history. In total, through generous philanthropic support, a record $5.3 million was invested to forward our innovative research and education programs.

A New Strategic Focus
This year our Board of Directors implemented a new three-year Strategic Plan to ensure the continued focus on our goal to improve patient care and find a cure for glaucoma. The new plan and its six strategic imperatives provide a framework for action in our priority focus areas: Research, Education, Communication, Philanthropy, Board Engagement, and Evaluation.

Research Initiatives: Advancing toward a Cure
With your support we funded eight individual research grants to expand our knowledge about glaucoma and funded multi-year collaborative research to find new ways to diagnose, manage, and prevent this blinding disease. The Catalyst for a Cure team — charged with identifying new, specific and sensitive biomarkers for glaucoma — continued to make significant progress in their research. The impact of their work will be valuable to both patients and eye doctors, potentially transforming how glaucoma is diagnosed and managed in the future.

Education and Awareness
Glaucoma Research Foundation is an important source of information and support for eye doctors, patients, and caregivers. This year a record 1.7 million visitors to our glaucoma.org website received accurate and helpful information. Our Gleams newsletter provided timely updates to households and doctors’ offices around the country, and through an educational grant, we printed a new 2013 edition of our booklet Understanding and Living with Glaucoma with more illustrations and up-to-date information on glaucoma treatment options.

Glaucoma 360
In February 2013, we held our second annual Glaucoma 360 New Horizons Forum, dedicated to advancing the development of new glaucoma therapies and improved diagnostic devices for patients. This unique gathering of medicine, industry, finance, and the FDA is designed to serve as a catalyst to advance novel ideas into clinical practice. More than 1,000 attended Glaucoma 360 events, including our Annual Gala and the Glaucoma Symposium CME.

Thank you for your continued support and ongoing partnership in our sight-saving endeavors. Together, we can truly make a difference in the lives of people with glaucoma.

Andrew G. Iwach, MD
Board Chair

Thomas M. Brunner
President and CEO
Research Collaboration is Speeding the Cure
Catalyst for a Cure Biomarkers Team Defines Milestones, Reports Progress

The goal of Catalyst for a Cure (CFC) “Biomarkers” collaboration is to discover clinically applicable biomarkers for the detection, monitoring and treatment of glaucoma.

The consortium has defined several early target milestones and work toward those milestones in now fully underway.

1. Search for and identify cells that reliably display changes in morphology and/or function and provide a means for early detection of glaucoma.

2. Test the hypothesis that changes in mitochondrial function or vascular flow represent early biomarkers for glaucoma.

3. Test the hypothesis that synapse loss in the inner retina is the earliest change in glaucoma that can be directly imaged in humans.

Progress toward these goals has been steady. All four labs are now fully established and running experiments. The group of four investigators talks regularly to discuss progress and members of the various groups travel to each other’s labs to carry out and discuss collaborative experiments.

Some key findings have emerged from these efforts that direct the focus for the next phase of experiments.

- Using a combination of genetic tools in a model of glaucoma, the CFC researchers have identified candidate early-detection cells. They have started testing markers that should enable them to determine whether these cells also exist in human retinas. They have also started testing a method to greatly aid visualization of these and other retinal cell types.

- The CFC team has built an Adaptive Optics Imaging system at Medical College of Wisconsin for the first imaging of retinal cells. This represents an innovative bringing together of modern genetic and in vivo imaging technologies. These imaging tools will also allow visualization of synaptic connections in the inner retina in vivo at unprecedented resolution.

- The CFC is establishing protocols for high-resolution imaging of mitochondrial transport and of inner retinal vasculature under conditions of reduced ganglion cell activity. They are also adopting chemical genetic approaches to represent a novel real-world relevant model of glaucoma.

Together, these approaches incorporate the expertise of all four laboratories and maximize the collaboration of these expert investigators. These research initiatives would not be possible to pursue, were it not for the collaborative nature of the Catalyst for a Cure consortium. The group will continue to expand consideration of new hypotheses and directions as the data sets evolve.

The Catalyst for a Cure (CFC) principal investigators
Alfredo Dubra, PhD
(The Eye Institute, Medical College of Wisconsin)

Andrew Huberman, PhD
(University of California, San Diego)

Jeffrey L. Goldberg, MD, PhD
(Shiley Eye Center, UC San Diego)

Vivek Srinivasan, PhD
(University of California, Davis)
Glaucoma Research Foundation provides seed funding for creative projects that hold promise and explore new research territory. All grants are in the amount of $40,000.

The 2013 Frank Stein and Paul S. May Grants for Innovative Glaucoma Research

John H. Fingert, MD, PhD, University of Iowa, Department of Ophthalmology and Visual Sciences, Iowa City, Iowa
Project: Molecular Genetic Study of Normal Tension Glaucoma using Transgenic Mice

Yvonne Ou, MD, University of California San Francisco, Department of Ophthalmology, San Francisco, California
Project: Investigating Axonal Death Pathways in Glaucoma

David Sretavan, MD, PhD, University of California San Francisco, San Francisco, California
Project: Pathophysiological Progression in Single RGC Axons Following Microscale Compressive Injury

The 2013 Shaffer Grants for Innovative Glaucoma Research

Anneke I. den Hollander, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Project: Dissecting the Genetic Causes of Congenital and Juvenile Glaucoma

The Dr. Miriam Yelsky Memorial Research Grant

M. Elizabeth Fini, PhD, University of Southern California, Institute for Genetic Medicine, Los Angeles, California
Project: Novel Mucins and Aqueous Outflow

Funding provided by a grant from the Merck Department of Continuing Education

Andras M. Komaromy, DrMedVet, PhD, Michigan State University, East Lansing, Michigan
Project: Gene Therapy in a Spontaneous Canine Model of Primary Open-Angle Glaucoma

Funding provided by a grant from The Alcon Foundation

Colleen M. McDowell, PhD, University of North Texas Health Science Center, Fort Worth, Texas
Project: Retina Ganglion Cell Subtype Specific Cell Death in a Mouse Model of Human Primary Open-Angle Glaucoma

Funding provided by a grant from The Alcon Foundation

Lin Wang, MD, PhD, Devers Eye Institute/Legacy Research Institute, Portland, Oregon
Project: Noninvasive Assessment of Dynamic Autoregulation in Optic Nerve Head

Funding provided by a grant from The Alcon Foundation
Total revenue for the fiscal year ended June 30, 2013 was a record $5.3 million. Through extraordinary support from our donors, $2.1 million was committed to forward innovative glaucoma research programs.

**Outstanding Philanthropic Support**
In addition to the generous annual support from our donors, many individuals also included Glaucoma Research Foundation in their estate plans. This year we received a $3 million bequest, the largest in our history, from Dr. Henry Adolph Sutro to establish two funds to support our research and education activities. Dr. Sutro made the gift in honor of his eye surgeon, Andrew G. Iwach, MD, Board Chair of Glaucoma Research Foundation. In addition to underwriting important research initiatives, this bequest also establishes the Drs. Henry and Frederick Sutro Memorial Lecture, to be held at the Glaucoma 360 annual meeting.

**Trusted Financial Stewardship**
Since 1978, with your support we have invested more than $40 million to advance essential research and education programs. We receive no government funding and rely on private and corporate philanthropy to nurture and sustain our programs. As a result of careful stewardship, 85 cents of every dollar donated goes directly to research and education.

We take pride in our 4-star (highest) rating from Charity Navigator, a leading independent evaluator of charitable organizations, we meet all twenty of the Better Business Bureau’s Standards for Charity Accountability, and we are listed on GuideStar.

Thank you for your personally significant contributions and keen interest to help speed the cure and raise awareness of this blinding disease.

---

**Frederick H. Brinkmann**
Treasurer
## Glaucoma Research Foundation
### Statement Of Financial Position As Of June 30, 2013*

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>$649,070</td>
<td>$595,208</td>
</tr>
<tr>
<td>Pledges and bequests receivable</td>
<td>67,180</td>
<td>96,170</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>76,571</td>
<td>72,899</td>
</tr>
<tr>
<td>Booklet inventory</td>
<td>14,744</td>
<td>42,376</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td>$807,565</td>
<td>$806,653</td>
</tr>
<tr>
<td><strong>NON-CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pledges and bequests receivable (net of present value discount and current portion)</td>
<td>1,500</td>
<td>-</td>
</tr>
<tr>
<td>Assets held in trust (at market value)</td>
<td>269,100</td>
<td>308,194</td>
</tr>
<tr>
<td>Investments (at market value)</td>
<td>4,766,365</td>
<td>4,325,208</td>
</tr>
<tr>
<td>Furniture and equipment (net of depreciation)</td>
<td>74,098</td>
<td>99,949</td>
</tr>
<tr>
<td>Permanently restricted cash</td>
<td>1,800,000</td>
<td>-</td>
</tr>
<tr>
<td><strong>TOTAL NON-CURRENT ASSETS</strong></td>
<td>$6,911,063</td>
<td>$4,733,351</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$7,718,628</td>
<td>$5,540,004</td>
</tr>
<tr>
<td><strong>LIABILITIES AND NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>35,540</td>
<td>39,719</td>
</tr>
<tr>
<td>Trusts, distributions payable, current portion</td>
<td>25,913</td>
<td>35,058</td>
</tr>
<tr>
<td>Grants payable</td>
<td>660,000</td>
<td>360,000</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT LIABILITIES</strong></td>
<td>$721,453</td>
<td>$434,777</td>
</tr>
<tr>
<td><strong>NON-CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liabilities to trust beneficiaries (at present value)</td>
<td>121,484</td>
<td>127,853</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td>$842,937</td>
<td>$562,630</td>
</tr>
<tr>
<td><strong>NET ASSETS</strong></td>
<td>$4,885,807</td>
<td>$4,732,231</td>
</tr>
<tr>
<td>Unrestricted</td>
<td>4,885,308</td>
<td>4,732,921</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>190,383</td>
<td>244,453</td>
</tr>
<tr>
<td>Permanently restricted net assets</td>
<td>1,800,000</td>
<td>-</td>
</tr>
<tr>
<td><strong>TOTAL NET ASSETS</strong></td>
<td>$6,875,691</td>
<td>$4,977,374</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td>$7,718,628</td>
<td>$5,540,004</td>
</tr>
</tbody>
</table>

---

*AUDITED FINANCIAL REPORT
In 2011, Frank Stein and Paul S. May established the Frank Stein and Paul S. May Grants for Innovative Glaucoma Research. Each year, their investment supports promising research to find new ways to diagnose, manage, and prevent glaucoma.

At the 2013 Annual Gala, Glaucoma Research Foundation honored Frank and Paul with The Catalyst Award in recognition for their exemplary leadership and extraordinary commitment to finding a cure for this blinding disease. Sadly, Paul passed away on September 12, 2013, but he left behind a remarkable legacy of goodwill through the numerous organizations he and Frank have generously supported.

Glaucoma Research Foundation is grateful to more than 3,000 individual, foundation and corporate donors who faithfully support our sight-saving endeavors each year. Thank you for your generosity.

In Appreciation
We express our deepest appreciation to all of our donors. Each and every gift is essential and assists us with forwarding our important mission. The following is a listing of contributors of $500 or more from July 1, 2012 to June 30, 2013.

CORPORATIONS AND FOUNDATIONS

Benefactors ($100,000 to $199,999)
The Alcon Foundation, Inc.
The Edward Joseph Daly Foundation
Partners Healthcare

Founders ($50,000 to $99,999)
The Allergan Foundation Lumenis, Inc.
Medical Research Charities

Pacesetters ($25,000 to $49,999)
Alcon Laboratories, Inc.
Merck Department of Continuing Education

Patrons ($10,000 to $24,999)
Abbott Medical Optics
Allergan, Inc.
Canon USA, Inc.
Carl Zeiss Meditec, Inc.
Carol Young Brooke Foundation
Dodge & Cox
Ellex, Inc.
Frank and Joseph Gila Fund
Genetech, Inc.
Mellam Family Foundation
Neighbor To Nation
Ono Pharma USA
Ora, Inc.
Santen, Inc.
The Palace Hotel
Union Bank
Versant Ventures

Sponsors ($5,000 to $9,999)
Allstate Life Insurance Company
Amakem Therapeutics
Delta Gamma Foundation
DSM Biomedical Inc.
Glaukos Corporation
Haag-Streit USA, Inc.
iCo Therapeutics, Inc.
Imperial Hotel, Tokyo
iScience Interventional Corporation
Kane County Cougars Baseball Club
Mobius Therapeutics, LLC
Nidek, Inc.
Ocular Therapeutix, Inc.
OptiMedica Corporation
Pfund Family Foundation
The Polakoff Foundation
Wells Fargo Advisors, LLC

President’s Club ($1,000 to $4,999)
Alloy Ventures, Inc.
ArceIerMittal Matching Gifts Program
Atherton Plastic Surgery
Bausch + Lomb
CPMC Foundation
Gibson, Dunn & Crutcher LLP
Heidelberg Engineering, Inc.
Icon Bioscience, Inc.
IOP Ophthalmics
IrideX Corporation
J. Lohr Vineyards & Wines
K. Arakelian Foundation
KPH Management, LLC
Macy’s Foundation
Mandarin Oriental, San Francisco
Maryland Charity Campaign
Mega Hertz
NeoMedix Corporation

Olive Riegel
Ophthalmic Mutual Insurance Company
Pacific Vision Foundation
Pebble Beach Company
San Francisco Toyota
Silverado Country Club
and Resort
Sinai Eye Education Corp.
of Detroit
Teachers Insurance and Annuity Association College Retirement Equities Fund
TearLab Corporation
The Magnum Group, Inc.
Transcend Medical, Inc.
Yellow Jacket River Guides

Contributors ($500 to $999)
Aetna Foundation, Inc.
Breitman Family Foundation, Inc.
Chevron Humankind Employee Funds
Concrete Technology Corporation
Delta Gamma, Diablo Valley Alumnae Chapter
Disneyland Resort
GE Foundation
Harrah’s Harvey’s Lake Tahoe
HCA & Co.
Hinomaru Limousine Co., Ltd.

Exceptional Donors (People Like You) Make Exceptional Research Possible
In Appreciation

JW Marriott San Francisco
Kaur Photography
Marines’ Memorial Association
Michael Merrill Design Center
Microsoft Matching Gifts Program
Modern Sailing School & Club
Monsanto Fund
Nonprofits’ Insurance Alliance of California
Palo Alto Hills Golf and Country Club
PRP Wine International
Select Auto Glass, Inc.
Surf & Sand Resort
Tenderloin Neighborhood Development Corporation
The Elena Melius Foundation
Valentine Wealth Management
William W. Kwan, MD Inc.

INDIVIDUALS

Visionairies ($200,000+)
Estate of Paul T. Frangias
Estate of Harriet N. MacGregor
The Henry A. Sutro Trust

Benefactors ($100,000 to $199,999)
Charlot and Dennis E. Singleton
Frank Stein and Paul S. May

Founders ($50,000 to $99,999)
Philip M. Eisenberg
Charitable Trust
Richard K. Hirayama

Pacesetters ($25,000 to $49,999)
Mr. and Mrs. F.T. Barr
June and Sean Otto
Frederick B. Foster and Frederick H. and Cynthia Brinkmann
Estate of Gwendolyn Madge Collins
Charles and Jane Kusek
Emmett Skinner, Jr.
Liz Stratton
Mona and Edward Zander

Patrons ($10,000 to $24,999)
Stuart Abelson, MBA
Thomas M. and Wallace Brunner

The Arlene J. Cumberland Revocable Trust
Anna L. Globe
The Hart 1998 Charitable Remainder Unitrust
Harry J. Krokus, Jr. Revocable Trust
Iris and Lawrence Lerner
Kathlyn McPherson Masneri and Arno P. Masneri Fund
Hiro and Betty Jean Ogawa
Deirdre Porter and Bradford Hall
Janet and Cary Rayment
David T. Richardson
Sandra and Marvin Rubin
Virginia M. Shaffer
Estate of Gladys M. Sinicrope
Matthew Tate, PhD
Estate of Miriam Yelsky

Sponsors ($5,000 to $9,999)
Fred Amoroso
Arlene Anthony
Lori and H. Allen Bouch
Sarah and Bill Brown
Clarence and Joan Coleman
Germaine and Timothy Dwyer, Wendy Dwyer Memorial
Mr. and Mrs. C.C. Edmunds
Carie and Larry Haimovitch
Irene Harris
Ann and H. Dunbar Hoskins, Jr., MD
Ms. Frances Vaughan Hunt
Andrew G. Iwash, MD
Roberta R.W. Kameda
Steve and Michele Kirsch
Lawrence S. Lipkind, DDS
Angela Nomellini and Kenneth E. Olivier
Sam and Denise Polakoff
Stephanie and N. D’Arcy Roche
Maria Constantino and Willem Roelands Foundation
Tamara and Paul Suslov Family Trust
Dr. James and Elizabeth Wise

CATALYST CIRCLE ($1,000 to $4,999)
Thea Amberg
Robert F. Amrhein
Weston and Jeanette Anderson
Eileen B. Ayer
Michael S. Barish
Dottie J. Barrett
Arthur A. Basham, MD
J. Bronwyn Bateman, MD
and Douglas Hershey, MD
Lezlie Beam
James and Virgene Beam
Arleen and Robert Belyea
Susan Benton
Dr. Joseph and Mrs. Helen Bernstein
Joan and Burt Berry
William and Suzan Blake
Robert F. Blitzer
E.M. Bluhm, PharmD
The Bodri Foundation of the Jewish Community Endowment
Richard Bon杜兰特
Warren Browner, MD, MPH
Dr. Edward & Mildred Cazafit
Family Foundation
Eugene Carlisle, MD
Paul G. Chaney
Hu H. Chao
Gregory Cheng and Dave Hooper
Nobuko Saito Cleary and Gary Cleary, PharmD, PhD
C. Seth Cunningham
Michael C. Davidson
Eugene de Juan, Jr., MD
Victoria and Donald F. DeMuth
Molly and Brett Dick
Ruth M. Drake Trust
Patrick W. Dwyer
Mark Eckstein
Carolyn Edward
Michael and Tracey Elfstrom
Peter Falzon
Anthony R. Fisher, PhD
Susanne Gerson
LaRue R. Gibson, Jr.
The Girdlestone Family
Gail and Harvey Glasser
May B. Gossett
Margaret and Joseph F. Govednik
Adrienne L. Graves, PhD
Nancy M. Graydon
Gary Greenberg
Meredith Gregory-Ksander
Carol M. Hall
Sharlene L. and Alfred D. Hall, PharmD
Louise and Rick Halprin, CPA
Robert T. Harker
Paul Heiman
Susan and John Hetherington, Jr., MD
Rosemary Hirsch

Mr. and Mrs. Morton Jeffrey Hoffman
Robert Holly
Daniel Hughes
Manraj Kohl
Michel M. Kapulica
Robert Karp
David and Janet Kline
Mrs. Amos Krausz
Charles Kueck
Andrew J. Kujawa
Patricia and Charles Lee
Frances and Jerry G. Leigh
Mrs. Paula Lenart
Alvin and Rosanne Levitt
Linda and Donald Linck, DDS
Amy and Rich Lipeles
Jane R. Lurie
Marian and Julius Tills
Endowment Fund of the Dallas Jewish Community Foundation
Elise A. Michael
Elizabeth B. and Carl V. Migliazzo, MD
Christopher M. Morgan
Seymour and Pearl Moskowitz
Sandra Moss
Kathryn K. Najafi-Tagol, MD
Carolyn M. Neerhof
Robert C. Nevins
Marjorie Nevitt
Vincent E. O’Brien
Judy F. Oliphant
Sanders M. Orr
Dana Park
Michael L. Penn, Sr.
Ms. Charlotte L. Petty
Regina Phelps
Elda and Richard Phillips
Walter R. Pieniazek
Michael Piser
Hardy and Ellie Prentice
Carol L. Rainey
Mr. Donald Robinson
Randolph C. Roeder
Karen and Harry Roth
John Russell
Rhett M. Schiffman, MD, MS, MHSA
F. Tracy Schilling
Lillian E. Schwarz
Todd Scott
W.B. Seaton
Michael W. Seefurth
Patrick Shuler
Saul Siemaska
Laine and Carl Smith
Stephen E. Smith
Amanda and Bruce E. Spivey, MD

Continued on page 10
In Appreciation

Robert Stamper, MD
Bill and Dorris Stewart
Joyce Suchsland
Shigemhi Sugiki, MD, FACS
Arthur S. Takahara
Catherine and Richard Tate
George Thomas
Dr. and Mrs. Thomas G. Todaro
Betty E. Toll
Samuel Urcis and Marion Zola
Michael and Ginger Valencia
Barbara and Robert Voss
Vincent A. Wallace
Richard and CB Watts
Lisa and Martin B. Wax, MD
Jane Weston, MD and Jan Horn, MD
Dr. and Mrs. George M. Weston
In Loving Memory of Daniel S. Weston
John Wied
Catherine and Charles Wilmoth
Diana Wilson
Matilda K. Yadla, MD
Jackie and Phillip Young
Cheryl and Thomas Young
Richard Zareck
Thelma H. Zeller

Contributors
($500 to $999)
Gwyndolen Allphin,
Anonymous, Joann Bach,
Bruce Bachelor, Schuyler
and Susie Bailey, Karla and
George Barber, Robert
Beadle, David Beery and Norm
Aframson, Mark A. Beisse,
Barbara J. Bethune, James K.
Boey, MD, Daniel G. Bond,
Walter M. Boomershine, Jr.,
Michael Boyd, Rosie Brewster-
Crowder, Jeffrey Brooks,
Susan Burgess, Michael and
Marilyn Cabak, William F.
Cael, Linda and Louis B.
Cantor, MD, Mary Cates,
Becky Chacko and Steve
A. Makai, Diane Charness,
Sophie Chastinot, Anthony
Chiu and A.J. Shepard, James
E. Coleman, Jr., Craig Corbitt
and Nancy Stoltz, Louise M.
and Thomas D. Cunningham,
Jr., Ken J. Damzonio, Robert
David, MD, Henry Davis,
Robert Davis, Norm Dito
and Steve Weiner, Robert R.
Drennan,
Jeffrey Drzazgowski, William
Edlund, Fred and Gaye
Ferronato, Danielle, Maureen
and Dan Fiarito, Dan Finkle,
Frank and Jeanne Fischer,
Paula and Michael Fritschen,
Paul Gacek, Margaret and
Russell Garvin, Marlene
Gersman, Marc Gleeson,
Susan Glikberg Hanson,
Brad Gold and Pat Khouri,
Daniel Hamilton, Tracy
Hammond, Paul Harvey,
Jr., Eve Higginbotham, MD,
Les and Eleanor Holve,
Dan Joraanstad and Robert
Hermann, Irene Kaus,
Joseph Kazaka and Joseph
E. Ruggiero, Sawako Kikuta,
Reginald and Grace King,
Michael and Aka Korek, Helen
C. Kuhn, Mrs. Helen C. Kuhn,
David Laudon, Jim Laufenberg
and Mike Daly, Tom Lehr, Don
R. Lenzi, DDS, Ken Leong,
Anthony and Pat Ley, Laura
and Steven M. Litinsky, MD,
Sharon L. Litsky and John F.
Sampson, Nancy Livingston
and Fred Levin, Joan B. Loeb,
Helyne and Lucas Loukides,
Larry and Nancy Ludgus,
Ashley C. Mccumber, Pearl
and Peter McFarland, James
P. Mondzelewski, MD, Alice
J. Streitwieser Morgan, Kathy
A. Mosher, Milton J. Mosk,
Ron Najafi, PhD, Judith Nevitt,
MD, Anibal Nieves, John and
Alice Osterman, Scott Pastor,
MD, Charles and Marjorie
Peterman, Karin Petersen,
Art and Carol Peterson, Terri
Pickering, MD, Estate of Erma
Pierce, Martha C. Powell,
Robert Powers, Barbara A.
Reilly, Janet Resele-Tiden,
Brian Roberts, Andrew
Rokfeffer, Cheryl Rowe-
Rendleman, PhD, Susan Ryu,
and MD and Michael Gaynon, MD,
Niko Saito, Charles L. Schmidt,
Tonya Schuler, Grace Seto,
Karen and Michelle Shuler,
Joan Simon, Carl and Elisabeth
Slenk, Michael Stedman,
Tania W. Stepanian, Roger
Stromberg, Craig Sundstrom,
Margaret and Richard
Tempero, Kathy M. Thomas,
Nicholas Thornsbury,
Thomas Van Haarlem, MD,
Brian Walsh, Brian A.
Welcome, MD, Katherine
Wenglikowski, Daniel White,
Franklin Williams, Michael
Winn, Bruce and Katrina
Woodske, Benjamin Yerxa,
PhD, Gisela K. Zebroski

ADDITIONAL CONTRIBUTORS
We are grateful to the more
than 3,000 donors who
have contributed this year to forward our
mission. Thank you for your steadfast support.

THE BLANCHE MATTHIAS SOCIETY
The Blanche Matthias Society
recognizes those individuals who have
included Glaucoma Research Foundation in
their estate plans. We are thankful to the following individuals that have
notified us of their intent to us as a beneficiary in
their wills, trusts, or other investment vehicles.

Steven Aberblatt
Marilynn Bagienski
Schuyler and Susie Bailey
Andrew Balaban
Gerald Beresniewicz
Barbara J. Bethune
Frances O. Blair
Thomas M. and Wallace
Brunner
Barbara R. Conway
Robert J. Drabkin
Gerald Entwistle
John Filozof
Carol Gasior
E. Y. and William O. Geisert
Sharon Koechlin
Barbara A. Livedakis
Craig T. Woodbury
And two anonymous members

For more information on the Blanche Matthias Society, visit our website at
glaucoma.org/involved
or contact us at
415-986-3162.

This honor roll is composed of major donors who
supported Glaucoma Research Foundation from July 1, 2012
to June 30, 2013. If your name has been omitted or there
is an error in the listing, we ask that you notify us at 251
Post Street, Suite 600, San Francisco, CA 94108 or call
415-986-3162.
Our Vision: A Future Free from Glaucoma Vision Loss
Board of Directors and Professional Staff

Board of Directors

Board Chair
Andrew G. Iwach, MD
Glaucoma Center of San Francisco
San Francisco, CA

President and CEO
Thomas M. Brunner
Glaucoma Research Foundation
San Francisco, CA

Vice Chair
Robert L. Stamper, MD
University of California
San Francisco, CA

Secretary
Bill Stewart
Apollo Programming Industries
Los Altos, CA

Treasurer
Frederick H. Brinkmann
Director, Information Technology (Retired)
Palo Alto, CA

Directors
J. Bronwyn Bateman, MD
Jules Stein Eye Institute
Los Angeles, CA

H. Allen Bouch
UBS Investment Bank
San Francisco, CA

C. Seth Cunningham
Clearwater Capital Partners
New York, NY

Timothy J. Dwyer
Private Investor
Woodside, CA

Adrienne L. Graves, PhD
Independent Director
San Francisco, CA

John W. Grunden, PharmD
Merck & Co., Inc.
Whitehouse Station, NJ

Rick Halprin, CPA
Alcon Laboratories, Inc.
Fort Worth, TX

John Hetherington, Jr., MD
University of California
San Francisco, CA

H. Dunbar Hoskins, Jr., MD
American Academy of Ophthalmology (Retired)
San Francisco, CA

Linda C. Linck
Delta Gamma Foundation
Lafayette, CA

Michael L. Penn, Sr.
Michael L. Penn & Associates
San Francisco, CA

Rhett M. Schiffman, MD, MS, MHSA
Neurotech Pharmaceuticals
Cumberland, Rhode Island

Dennis E. Singleton
Speiker Partners
Menlo Park, CA

Art Takahara
De Anza Manufacturing, Inc.
Sunnyvale, CA

George E. Thomas
Insurance Management Consultant
San Francisco, CA

Martin B. Wax, MD
PanOptica, Inc.
Bernardsville, NJ

Mona Zander
Carmel, CA

Founder
Robert N. Shaffer, MD
(1912 - 2007)

Honorary Advisory Board

F. T. Barr
Afex International, Inc.
Houston, TX

June Behrendt Otto
The Edward J. Daly Foundation
San Francisco, CA

Sarah Brown
San Francisco, CA

Robert Drabkin
Los Angeles, CA

Steven Kirsch
San Jose, CA

Roger McGuinn
Windemere, FL

Robert C. Nevins
Lafayette, CA

David E. I. Pyott
Allergan, Inc.
Irvine, CA

Cary R. Raymond
Alcon, Inc. (Retired)
Ft. Worth, TX

Professional Staff

Thomas M. Brunner
President and CEO

Nancy Graydon
Executive Director of Development

Andrew L. Jackson
Director of Communications

Catalina San Agustin
Director of Operations

Rebekah L. Stout, CMP
Director of Special Events

Aileen Trieu
Assistant Director, Special Events and Annual Fund

Christie D’Angelo
Special Events and Volunteer Coordinator

Michelle Davidson
Administrative Assistant
GRF Council and Scientific Advisors

GRF Council
A national leadership council of glaucoma specialists dedicated to improving access to educational materials for all glaucoma patients.

Chair, GRF Council
Carl Migliazzo, MD

GRF Councilors
John S. Cohen, MD
Robert Feldman, MD
L. Jay Katz, MD
Steve Litinsky, MD
Charles McMahon, MD
Michael Sakamoto, MD
Bradley Schuster, MD
Oluwatosin Smith, MD
Ruth Williams, MD

Associate Councilors
Stuart F. Ball, MD
Robert J. Barnes, MD
Michael S. Berlin, MD
Steven V.L. Brown, MD, FACS
Dean Carlson, MD
Randy Craven, MD
Robert J. Derick, MD
Monte Dirks, MD
Amish Doshi, MD
Doreen Fazio, MD
Gloria P. Fleming, MD
David Gilbert, MD
Linda Greff, MD
Agnes Huang, MD
Dan Jewelewicz, MD
Martin B. Kaback, MD
Anup Khatana, MD
Douglas Kohl, MD
Michael S. Korey, MD
Rohit Krishna, MD
Linda Lawrence, MD
William E. Layden, MD
Richard Lehrer, MD
Anne Miller, MD
Kevin Miller, MD
Johann Ohly, MD
David J. Palmer, MD
Scott A. Pastor, MD
Cindy Penzler, MD
Andrew Prince, MD
Andrew Rabinowitz, MD
George Reiss, MD
Sonja W. Schluter, MD, MPH
Arthur L. Schwartz, MD
Gail F. Schwartz, MD
Rajesh Shetty, MD
Charles Eric Shrader, MD
Michael Stiles, MD
Thomas Tayeri, MD
Jeffrey Zink, MD

Scientific Advisors

Jack P. Antel, MD
Montreal Neurological Institute
Ben Barres, MD, PhD
Stanford University School of Medicine
Balwantray Chauhan, PhD
Dalhousie University, Nova Scotia
George A. Cioffi, MD
Columbia University College of Physicians and Surgeons
Anne L. Coleman, MD, PhD
Jules Stein Eye Institute
Scott Fraser, PhD
University of Southern California
Christopher A. Girkin, MD
University of Alabama at Birmingham
David S. Greenfield, MD
University of Miami
Leonard A. Levin, MD, PhD
McGill University Health Centre
Steven L. Mansberger, MD, MPH
Devers Eye Institute/Legacy Health
Martin Raff, MD
University College, London
Joel S. Schuman, MD
University of Pittsburgh School of Medicine
David W. Sretavan, MD, PhD
University of California San Francisco
Ernst R. Tamm, MD
University of Regensburg, Germany
Russell Van Gelder, MD, PhD
University of Washington
Monica Vetter, PhD
University of Utah
Martin B. Wax, MD
PanOptica, Inc.
Arthur J. Weber, PhD
Michigan State University
Janey L. Wiggs, MD, PhD
Massachusetts Eye & Ear Infirmary